Adnan A. Kadi

3.6k total citations
171 papers, 3.0k citations indexed

About

Adnan A. Kadi is a scholar working on Molecular Biology, Organic Chemistry and Oncology. According to data from OpenAlex, Adnan A. Kadi has authored 171 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Molecular Biology, 62 papers in Organic Chemistry and 42 papers in Oncology. Recurrent topics in Adnan A. Kadi's work include PI3K/AKT/mTOR signaling in cancer (33 papers), Cancer therapeutics and mechanisms (32 papers) and Lung Cancer Treatments and Mutations (29 papers). Adnan A. Kadi is often cited by papers focused on PI3K/AKT/mTOR signaling in cancer (33 papers), Cancer therapeutics and mechanisms (32 papers) and Lung Cancer Treatments and Mutations (29 papers). Adnan A. Kadi collaborates with scholars based in Saudi Arabia, Egypt and China. Adnan A. Kadi's co-authors include Mohamed W. Attwa, Ali S. Abdelhameed, Hany W. Darwish, Haitham AlRabiah, Ali A. El‐Emam, Omar A. Al‐Deeb, Tarek M. Ibrahim, El‐Sayed E. Habib, Sawsan M. Amer and A. F. M. Motiur Rahman and has published in prestigious journals such as SHILAP Revista de lepidopterología, PLoS ONE and Chemical Communications.

In The Last Decade

Adnan A. Kadi

161 papers receiving 3.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Adnan A. Kadi Saudi Arabia 32 1.5k 1.3k 600 463 236 171 3.0k
Mohamed W. Attwa Saudi Arabia 27 396 0.3× 907 0.7× 498 0.8× 470 1.0× 214 0.9× 141 1.7k
Ali S. Abdelhameed Saudi Arabia 29 402 0.3× 1.5k 1.1× 660 1.1× 228 0.5× 112 0.5× 153 2.5k
Ahmed H. Bakheit Saudi Arabia 30 792 0.5× 1.5k 1.2× 819 1.4× 89 0.2× 98 0.4× 145 2.7k
Simon J. F. Macdonald United Kingdom 34 2.3k 1.6× 1.7k 1.3× 314 0.5× 161 0.3× 230 1.0× 111 4.5k
Paul M. Loadman United Kingdom 37 585 0.4× 2.1k 1.6× 1.1k 1.8× 249 0.5× 268 1.1× 152 4.0k
Stephen Castellino United States 26 582 0.4× 817 0.6× 550 0.9× 216 0.5× 120 0.5× 49 2.3k
Shijun Wen China 36 1.2k 0.8× 2.0k 1.5× 511 0.9× 243 0.5× 125 0.5× 101 3.7k
Stefania Nobili Italy 32 773 0.5× 1.8k 1.4× 2.1k 3.5× 407 0.9× 188 0.8× 97 4.3k
Bernard Faller Switzerland 24 388 0.3× 1.0k 0.8× 675 1.1× 79 0.2× 345 1.5× 38 2.9k
Wenfang Xu China 37 1.7k 1.1× 3.0k 2.4× 1.6k 2.6× 154 0.3× 86 0.4× 266 5.2k

Countries citing papers authored by Adnan A. Kadi

Since Specialization
Citations

This map shows the geographic impact of Adnan A. Kadi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adnan A. Kadi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adnan A. Kadi more than expected).

Fields of papers citing papers by Adnan A. Kadi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adnan A. Kadi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adnan A. Kadi. The network helps show where Adnan A. Kadi may publish in the future.

Co-authorship network of co-authors of Adnan A. Kadi

This figure shows the co-authorship network connecting the top 25 collaborators of Adnan A. Kadi. A scholar is included among the top collaborators of Adnan A. Kadi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adnan A. Kadi. Adnan A. Kadi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Attwa, Mohamed W., Ali S. Abdelhameed, Haitham AlRabiah, & Adnan A. Kadi. (2025). Assessment of the metabolic stability of avapritinib in human liver microsomes using a fast and green UPLC-MS/MS method: screening for structural alarms associated with metabolic lability and in silico toxicity. Analytical Methods. 17(37). 7431–7443. 3 indexed citations
2.
Attwa, Mohamed W., Ali S. Abdelhameed, & Adnan A. Kadi. (2025). Validated green ultra-fast UPLC-MS/MS method for the quantification of fedratinib in an HLM matrix: application to in vitro and in silico metabolic stability studies. Analytical Methods. 17(27). 5714–5725. 4 indexed citations
3.
Attwa, Mohamed W., Ali S. Abdelhameed, & Adnan A. Kadi. (2025). An ultra-fast UPLC-MS/MS approach for the quantification of baricitinib in the HLM matrix: greenness assessment with application to in vitro and in silico metabolic stability studies. Analytical Methods. 17(13). 2718–2732. 8 indexed citations
4.
5.
6.
Attwa, Mohamed W., Ali S. Abdelhameed, & Adnan A. Kadi. (2024). Ultra-fast UPLC–MS/MS approach for estimating X-376 in human liver microsomes: Evaluation of metabolic stability via in silico software and in vitro analysis. Journal of Pharmacological and Toxicological Methods. 128. 107540–107540. 4 indexed citations
7.
Attwa, Mohamed W., Haitham AlRabiah, Ali S. Abdelhameed, & Adnan A. Kadi. (2024). Assessment of the in vitro metabolic stability of CEP-37440, a selective FAK/ALK inhibitor, in HLMs using fast UPLC–MS/MS method: in silico metabolic lability and DEREK alerts screening. Frontiers in Chemistry. 12. 1323738–1323738. 1 indexed citations
8.
9.
10.
Attwa, Mohamed W., Aishah M. Alsibaee, Haya I. Aljohar, Ali S. Abdelhameed, & Adnan A. Kadi. (2023). Development of a Fast and Sensitive UPLC–MS/MS Analytical Methodology for Fenebrutinib Estimation in Human Liver Microsomes: In Vitro and In Silico Metabolic Stability Evaluation. Separations. 10(5). 302–302. 12 indexed citations
11.
Attwa, Mohamed W., Ahmed H. Bakheit, Ali S. Abdelhameed, & Adnan A. Kadi. (2023). An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib. Molecules. 28(20). 7220–7220. 2 indexed citations
12.
Attwa, Mohamed W., Ali S. Abdelhameed, & Adnan A. Kadi. (2023). A Sensitive, Green, and Fast LC–MS/MS Analytical Method for the Quantification of Ribociclib: Evaluation of the Metabolic Stability in HLMs. Separations. 10(9). 472–472. 1 indexed citations
13.
Attwa, Mohamed W., Ali S. Abdelhameed, Aishah M. Alsibaee, & Adnan A. Kadi. (2023). A Rapid and Sensitive UPLC-MS/MS Method for Quantifying Capmatinib in Human Liver Microsomes: Evaluation of Metabolic Stability by In Silico and In Vitro Analysis. Separations. 10(4). 247–247. 18 indexed citations
14.
Attwa, Mohamed W., et al.. (2020). In silico and in vitro metabolism of ribociclib: a mass spectrometric approach to bioactivation pathway elucidation and metabolite profiling. RSC Advances. 10(38). 22668–22683. 30 indexed citations
15.
Attwa, Mohamed W., Adnan A. Kadi, Ali S. Abdelhameed, & Hassan A. Alhazmi. (2020). <p>Metabolic Stability Assessment of New PARP Inhibitor Talazoparib Using Validated LC–MS/MS Methodology: In silico Metabolic Vulnerability and Toxicity Studies</p>. Drug Design Development and Therapy. Volume 14. 783–793. 38 indexed citations
16.
17.
Attwa, Mohamed W., Adnan A. Kadi, & Ali S. Abdelhameed. (2018). Reactive intermediates and bioactivation pathways characterization of avitinib by LC–MS/MS: In vitro metabolic investigation. Journal of Pharmaceutical and Biomedical Analysis. 164. 659–667. 38 indexed citations
18.
Darwish, Hany W., et al.. (2018). Investigation of metabolic stability of the novel ALK inhibitor brigatinib by liquid chromatography tandem mass spectrometry. Clinica Chimica Acta. 480. 180–185. 32 indexed citations
19.
Asiri, Yousif A., et al.. (2011). Comparative bioavailability study of cefuroxime axetil (equivalent to 500 mg cefuroxime/tablet) tablets (Zednad® versus Zinnat®) in healthy male volunteers. International Journal of Clinical Pharmacology and Therapeutics. 49(9). 571–576. 4 indexed citations
20.
Morvan, Julie, et al.. (2009). L’écho-Doppler puissance est-il un bon témoin de l’agressivité du cancer de la prostate ?. Journal de Radiologie. 90(3). 299–303. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohamed W. Attwa Breakdown of academic impact, for papers by Ali S. Abdelhameed Breakdown of academic impact, for papers by Ahmed H. Bakheit Breakdown of academic impact, for papers by Simon J. F. Macdonald Breakdown of academic impact, for papers by Paul M. Loadman Breakdown of academic impact, for papers by Stephen Castellino Breakdown of academic impact, for papers by Shijun Wen Breakdown of academic impact, for papers by Stefania Nobili Breakdown of academic impact, for papers by Bernard Faller Breakdown of academic impact, for papers by Wenfang Xu
Rankless by CCL
2026